Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

JAMA - 28 Sept 2005

Lanfear David E, Jones Philip G, Marsh Sharon, Cresci Sharon, McLeod Howard L, Spertus John A

Abstract excerpt

CONTEXT: Previous data support an association between polymorphisms of the beta1- and beta2-adrenergic receptors (ADRB1 and ADRB2) and surrogate end points of response to beta-adrenergic blocker therapy. However, no associations between these polymorphisms and mortality have been demonstrated. OB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Angina, Unstable
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myocardial Infarction

Share to Polymorphism, Genetic

Share to Receptors, Adrenergic, beta-1

Share to Receptors, Adrenergic, beta-2

Share to Survival Analysis

Source

Identifiers

PMID: 16189366
DOI: 10.1001/jama.294.12.1526

Genes

ADRB2
ADRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16189366-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.PMID 16189366Read ↗

Beta2-adrenergic receptor genotype predicts survival: implications and future directions.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in HypertensionSemantic proximity Read ↗

Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers.Semantic proximity Read ↗

Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.Semantic proximity Read ↗

Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.Semantic proximity Read ↗

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.Semantic proximity Read ↗

Clinical and genetic modifiers of long-term survival in heart failure.Semantic proximity Read ↗

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.